Pace® Life Sciences to Lead Targeted Drug Delivery Roundtable at Oligo & Peptides HubXchange
Learn more
With deep expertise in protein- and nucleic acid–based therapeutics, Frank brings a forward-looking perspective to emerging modalities and technologies. He plays a key role in evaluating and implementing scientific approaches that enable Pace to support effective, efficient research and development as the industry evolves.
Frank joined Pace® in 2017 through the acquisition of Wolfe Laboratories.
Frank earned his PhD from the University of Virginia.
Get in touch
Whether you’re shaping early plans or preparing to scale, our teams are here to help you move forward with clarity and confidence. Start the conversation and we’ll get back to you quickly.
